Clinical Research Site

Dallas, Texas 75390-8898

5 studies enrolling now · 15 studies all time

What they study most

ADHD, Agitation in Patients With Dementia of the Alzheimer's Type, Binge-Eating Disorder, Depression, Essential Hypertension, Fibromyalgia, Major Depressive Disorder, Major Depressive Disorder With Excessive Daytime Sleepiness Symptoms, Membranous Nephropathy, Pulmonary Aspergillosis, Treatment Resistant Depression

Studies at this site

• Elucidating TAAR-1, Dopamine, and Norepinephrine in Binge Eating Disorder Using Solriamfetol — Recruiting now
• Clinical Assessment of Response in the Treatment of Depression With Daytime Sleepiness Using Solriamfetol — Recruiting now
• Fibromyalgia Response With Esreboxetine Evaluated Using a Randomized Withdrawal Research Design — Recruiting now
• A Study to Evaluate the Efficacy of AXS-05 Compared to Bupropion in Preventing the Relapse of Depressive Symptoms — Recruiting now
• An Open-label Safety Study of PC945 (Opelconazole) Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients (OPERA-S Study) — Completed
• Efficacy and Safety of VB119 in Subjects With Membranous Nephropathy — Stopped early
• A Study to Assess the Efficacy and Safety of Solriamfetol in Subjects With ADHD (FOCUS) — Completed
• Open-Label Safety Study of AXS-05 in Subjects With TRD (EVOLVE) — Stopped early
• Progressing TAAR-1, Dopamine, and Norepinephrine in Depression Using Solriamfetol — Completed
• Open-Label Safety Study of Solriamfetol in Subjects With Binge Eating Disorder — Enrolling by invitation
• Efficacy, Safety and Tolerability of AVP-786 for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type — Completed
• Open-Label Safety Study of AXS-05 in Subjects With Depression — Completed
• A Trial of AXS-05 in Patients With Major Depressive Disorder — Completed
• Mechanistic Evaluation of Response in TRD (MERIT) — Completed
• An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension — Completed